CHO H01

Drug Profile

CHO H01

Alternative Names: CHO-H01; Glyco-engineered anti-CD20 antibody

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Academia Sinica
  • Developer CHO Pharma
  • Class Antibodies; Antineoplastics
  • Mechanism of Action CD20 antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 20 Jul 2017 CHO Pharma plans a phase I trial for Follicular lymphoma (Monotherapy, Second-line therapy or greater) in USA (IV) in October 2017 (NCT03221348)
  • 20 Jul 2017 CHO Pharma in-licenses homogeneous antibody drugs from Academia Sinica
  • 20 Jul 2017 CHO Pharma has patent protection for Homogeneous antibody technology in USA (CHO Pharma website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top